1. Fava G, A, Rafanelli C: Iatrogenic Factors in Psychopathology. Psychother Psychosom 2019;88:129-140. doi: 10.1159/000500151
2. Grace SL, Medina-Inojosa JR, Thomas RJ, Krause H, Vickers-Douglas KS, Palmer BA, et al. Antidepressant Use by Class: Association with Major Adverse Cardiac Events in Patients with Coronary Artery Disease. Psychother Psychosom. 2018;87(2):85–94.
3. Chouinard G, Samaha A-N, Chouinard V-A, Peretti C-S, Kanahara N, Takase M, et al. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy. Psychother Psychosom. 2017;86(4):189–219.
4. Heinrich TW, Owen JR, Pawar DS. A Psychopharmacology Guide by Psychiatrists for Non-psychiatrists. In: Sobin W. (eds) Using Central Neuromodulators and Psychological Therapies to Manage Patients with Disorders of Gut-Brain Interaction. Springer, Cham. 2019. https://doi.org/10.1007/978-3-030-18218-2_3
5. Lahijani SC, Harris KA. Medical Complications of Psychiatric Treatment: An Update. Crit Care Clin. 2017 Jul;33(3):713–34
6. Nicol GE, Ivanov I. Getting to Precision Psychopharmacology in Child Psychiatry: The Value of Adverse Treatment Effects. J Child Adolesc Psychopharmacol. 2021 Feb 1;31(1):1–3.
7. Montejo AL, Lourenço M. Editorial: Safety and Tolerability of Psychotropic Compounds. Front Neurosci. 2020;14:509. Published 2020 Jun 18. doi:10.3389/fnins.2020.00509
8. Tomba E, Guidi J, Fava GA. What psychologists need to know about psychotropic medications. Clin Psychol Psychother. 2018 Mar;25(2):181–7.
9. Fava GA, Belaise C. Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience. Psychother Psychosom. 2018;87(5):257–67.
10. Braillon A, Lexchin J, Noble JH, Menkes D, M’sahli L, Fierlbeck K, et al. Challenging the promotion of antidepressants for nonsevere depression. Acta Psychiatr Scand. 2019 Mar;139(3):294–5.
11. Aguilar L, Lorenzo C, Fernández-Ovejero R, Roncero C, Montejo AL. Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin. Front Pharmacol. 2019;10:281.
12. Barata PC, Santos MJ, Melo JC, Maia T. Olanzapine-Induced Hyperprolactinemia: Two Case Reports. Front Pharmacol. 2019;10:846.
13. Lahijani SC, Harris KA. Medical Complications of Psychiatric Treatment. Critical Care Clinics, 2017. 33(3), 713–734. doi:10.1016/j.ccc.2017.03.008
14. Goldberg SG, Wagner K. American Psychological Association practice guidelines for psychopharmacology: Ethical practice considerations for psychologists involving psychotropic use with children and adolescents. J Clin Psychol. 2019;75(3):344–63.